Quantcast
Connect with us

Experimental chikungunya vaccine shows promise in first human trials

Published

on

By Will Dunham

WASHINGTON (Reuters) – An experimental vaccine being developed by U.S. government scientists to prevent the painful mosquito-borne viral disease chikungunya has shown promise in its first human trials but remains years away from approval for widespread use.

In a study published on Thursday in the Lancet medical journal, National Institutes of Health scientists said the vaccine elicited an impressive immune response in all 25 adult volunteers who took part and caused no worrisome side effects.

“We believe it is a highly promising vaccine given how well tolerated it was and how robust the immune responses were,” said the leader of the study, Dr. Julie Ledgerwood of the NIH’s National Institute of Allergy and Infectious Diseases.

Infection with the virus, spread by two mosquito species, typically is not fatal but can cause debilitating symptoms including fever, headache and severe joint pain lasting weeks or months. There is no current treatment and no licensed vaccine to prevent it.

ADVERTISEMENT

It showed up for the first time in the Americas late last year. In the United States, locally transmitted infections – as opposed to infections in Americans traveling abroad – have been reported for the first time this year.

The early-stage clinical trial involved 25 healthy American volunteers ages 18 to 50 years old who were given one of three dosage levels of the vaccine in three injections over a 20-week period.

The volunteers were not exposed to the chikungunya virus, but their immune response was measured in the form of neutralizing antibodies – proteins produced by a special type of white blood cell that defends a person from an invading virus.

ADVERTISEMENT

An immune response was seen in most of the volunteers after the first vaccination. Following the second, all exhibited high levels of antibodies. There also was a significant increase in antibodies after the third injection.

The antibodies lasted a long time and were present in all of the volunteers six months following their final shot.

This was a so-called Phase I trial testing the safety of a vaccine and looking at dosage ranges. Before securing regulatory approval, the vaccine would need to go through a Phase II trial using a larger group of people to test potential effectiveness and further evaluate safety. Next would be a Phase III trial with large numbers of people to confirm effectiveness and safety.

ADVERTISEMENT

The vaccine already was shown to protect rhesus monkeys from chikungunya.

“A Phase II trial likely would take several more years, both for the production of vaccine as well as development and completion of the trial,” Ledgerwood said.

Ledgerwood said the NIH needs to work with private organizations or industry partners to move forward.

ADVERTISEMENT

“At least one such potential partner is interested,” she added without saying who it was. “For most vaccines, development takes decades. We don’t think it should take that long for this vaccine.”

Vaccines often are made from killed viruses or weakened live viruses. This one is different. It is a virus-like particle (VLP) vaccine similar to the type used against human papillomavirus (HPV).

(Reporting by Will Dunham)


Report typos and corrections to: [email protected]. Send news tips to: [email protected].
READ COMMENTS - JOIN THE DISCUSSION
Continue Reading

Facebook

US sanctions Chinese oil trader for violating Iran restrictions: Pompeo

Published

on

The United States is placing a leading Chinese oil importer on its sanctions blacklist for trading in Iranian crude, Secretary of State Mike Pompeo announced Monday.

"As part of that maximum pressure campaign, I am announcing that the United States is imposing sanctions on the Chinese entity Zhuhai Zhenrong and its chief executive Youmin Li," Pompeo said in a speech.

"They violated US law by accepting crude oil," he said.

The announcement was the latest step by Washington to ratchet up economic pressure on Tehran over its alleged military activities in the Middle East and its nuclear program by taking aim at business partners.

Continue Reading

Facebook

French inventor to hover across English Channel on ‘flyboard’

Published

on

A French inventor aims to soar across the English Channel this week on a jet-powered "flyboard", despite authorities warning the stunt is a danger to shipping.

Former jet-skiing champion Franky Zapata has pledged to go ahead on Thursday on his device, which can reach speeds up to 190 kilometres an hour (118 mph).

It will come 10 days days after the entrepreneur wowed crowds when he flew above the Champs-Elysees boulevard in Paris in front of President Emmanuel Macron for the annual July 14 military parade.

But authorities are divided over the daredevil venture, which will mark 110 years to the day since Frenchmen Louis Bleriot made the first aeroplane flight across the Channel.

Continue Reading
 

Facebook

Meghan McCain snaps at Sunny Hostin for daring to disagree with her about Alexandria Ocasio-Cortez

Published

on

Meghan McCain slammed President Donald Trump for hurling racist abuse at four Democratic congresswomen to heighten divisions in his rival party, and then framed the debate in the exact same way he has.

The conservative co-host on "The View" condemned the president's statements urging the four first-year lawmakers to return to their home countries as racist, and then complained that one of their chiefs of staff had accused moderate Democrats of turning a blind eye to racism.

"I think the politics of this is fascinating," McCain began. "We spent our entire week last week talking about how racist and xenophobic the original comments and the chants were, and I stand by that statement."

Continue Reading
 
 
 

Copyright © 2019 Raw Story Media, Inc. PO Box 21050, Washington, D.C. 20009 | Masthead | Privacy Policy | For corrections or concerns, please email [email protected]

Join Me. Try Raw Story Investigates for $1. Invest in Journalism. Escape Ads.
close-image